Primary Refractory Double Hit Diffuse Large B Cell Lymphoma: Complete Response to Ibrutinib and Rituximab
Double hit lymphoma (DHL) associated with
translocations in MYC and BCL-2 or BCL-6 gene accounts
for approximately 5-10 % of all diffuse large B cell
lymphoma (DLBCL) [1]. These patients are distinct from
double-expressers who stain positive on
immunohistochemistry for MYC and BCL2 or BCL6 accounting for approximately 25-35% of all DLBCL. Double expresser DLBCL have relatively poor outcomes but DHL is associated with extremely aggressive course and poor prognosis. With R-CHOP, R-EPOCH or similar induction therapy a complete response rates of 30-70% have been reported for DHL with 5 years survival of only 27-36%.
Follow below link for full article
https://medwinpublishers.com/JES/JES16000121.pdf
immunohistochemistry for MYC and BCL2 or BCL6 accounting for approximately 25-35% of all DLBCL. Double expresser DLBCL have relatively poor outcomes but DHL is associated with extremely aggressive course and poor prognosis. With R-CHOP, R-EPOCH or similar induction therapy a complete response rates of 30-70% have been reported for DHL with 5 years survival of only 27-36%.
Follow below link for full article
https://medwinpublishers.com/JES/JES16000121.pdf